Behringwerke Aktiengesellschaft

Dade Behring Marburg Gmbh

Hoechst Aktiengesellschaft

Aventis Pharma Deutschland, Gmbh

Siemens Healthcare Diagnostics Products Gmbh

Heochst Aktiengesellschaft

Laboratoires Hoechst

Manfred Gerken

Stefan Knapp

Stefan Brust

Lutz G Guertler

Klaus Bosslet

Cenek Kolar

Dieter Hoffmann

Peter Hermentin

Hans P Kraemer

Claude Monneret

Jorg Czech

Jean-Claude Florent

Ernst Raab

Rainer Straub

Heinz-Werner Kleemann

Gary A Flynn

Gerhard Dickneite

Wolfgang Linz

Gerhard Seemann

Ulrich Stache

Michael Paal

Jean-Claude Jacquesy

Bernd Jablonka

Michel Koch

Hans H Sedlacek

Jean-Pierre Gesson

Hans-Ulrich Schorlemmer

Hans G Berscheid

Dirk Bottger

Francedillaois Tillequin

Bernhard Seuring

Martine Mondon

Barbara Ann Anderson

J Org Czech

Werner Seiz

Dieter Hoffman

Gilbert Gaudel

Brigitte Renoux

Reiner Straub

Monika Grimm

Frederic Schmidt

Matthias Blumrich

Hans Peter Kraemer

Hans Gerd Berscheid

Immunologically active peptides which are derived from a novel immunodeficiency virus which has the designation MVP5180/91 are described. A diagnostic composition containing such a peptide and methods of detecting an antibody against a retrovirus that causes immune deficiency using such diagnostic composition are also described. A kit containing the immunologically active peptides is also described. An immunogen and method of immunizing a mammal against HIV infection using the immunologically active peptides is described. DNA encoding the peptides and methods of detecting nucleic acids encoding HIV viruses are also described.

Antigenic HIV gp41 chimeric polypeptides comprising the MVP5180/91 epitope SKGKLIS

Immunologically active peptides which are derived from a novel immunodeficiency virus which has the designation MVP5180/91 are described. A diagnostic containing such a peptide and methods of detecting an antibody against a retrovirus that causes immune deficiency using such diagnostic composition are also described. A kit containing the immunologically active peptides is also described. An immunogen and method of immunizing a mammal against HIV infection using the immunologically active peptides is described. DNA encoding the peptides and methods of detecting nucleic acids encoding HIV viruses are also described.

Peptides derived from a retrovirus of the HIV group and their use

This invention discloses and claims a series of mercaptoacetylamide derivatives of formula I. Also disclosed and claimed are pharmaceutical compositions incorporating these compounds and processes for preparing said compounds. The use of said compounds for inhibition of the enzymes angiotensin converting enzyme and neutral endopeptidase, and for the treatment of hypertension and congestive heart failure are also disclosed and claimed

Mercaptoacetylamide derivatives, a process for their preparation and their use

The present invention is directed toward nucleic-acid based methodologies for the detection of human immunodeficiency virus (HIV) nucleic acids in a sample. A novel HIV-1 isolate, designated MVP5180/91, was isolated from a West African Cameroonian patient with immunodeficiency. Nucleic acid and amino acid sequence comparisons of this isolate, with other HIV-1 strains of subtypes A-E and HIV-2 isolates, demonstrated that this virus shares only limited homology with other known HIV-1 and -2 isolates. However, this virus does display some genetic relatedness to another Cameroonian isolate designated ANT-70. These viruses form the basis for a new HIV-1 group which has been designated subtype O. An immunologically important epitope, corresponding to amino acids 601-623 of the MVP5180/91 transmembrane envelope glycoprotein, was identified. Labeled nucleic acids can be prepared from the nucleotide sequence encoding this region and employed in standard hybridization assays to detect HIV-1 nucleic acids. Alternatively, oligonucleotide primers can also be prepared from this region and employed in polymerase chain reaction (PCR) assays to detect viral-specific nucleic acids.

Methodologies for the detection of human immunodeficiency virus nucleic acids employing oligonucleotide primer derived from the HIV-1 MVP5180/91 genome

A preparation having increased in vivo tolerability comprising a glycosyl-Y[--C(.dbd.Y)--X--].sub.p --W(R).sub.n --X--C(.dbd.Y)-active compound, sugar or sugar alcohol and, optionally divalent ions, and a pharmaceutically tolerable carrier.

Preparation having increased in vivo tolerability

Prodrugs for the therapy of tumors and inflammatory disorders

Semisynthetic diastereomerically pure N-glycidylanthracyclines, a process for the stereoselective preparation thereof and the use thereof as cytostatics. The invention relates to anthracyclines having cytostatic activity and the formula I, which are, where appropriate, in the form of a salt with an inorganic or organic acid, ##STR1## in which R.sup.1 is hydrogen or a hydroxyl group,

Semisynthetic diastereomerically pure N-glycidylanthracyclines, a

Glycosylated prodrugs, their method of preparation and their uses

The invention relates to new anthracycline derivatives having cytostatic activity and the general formula I, ##STR1## which can optionally also be in the form of an acid addition salt of physiologically acceptable inorganic or organic acids, where R.sup.1 is hydrogen or a hydroxyl group, R.sup.2 is hydrogen, a hydroxyl or a methoxy group, R.sup.3 is hydrogen or a hydroxyl group, R.sup.4 is hydrogen or a hydroxyl group, R.sup.5 hydrogen, a hydroxyl or a methoxycarbonyl group, R.sup.6 is CH.sub.2 CH.sub.3, COCH.sub.3, COCH.sub.2 OH, CHOHCH.sub.3 or CHOHCH.sub.2 OH and R.sup.7 is an organic substituent which has 2 to 6 carbon atoms and which contains at least one oxygen, nitrogen or sulfur atom or a C--C double bond or a C--C triple bond, it being possible for the double bond also to be a constituent of a heteroaromatic system and for the oxygen, nitrogen or sulfur atom to be a constituent of an open-chain or heterocyclic system, to a process for the preparation thereof and to the use thereof in a pharmaceutical.

Anthracycline derivatives having cytostatic activity

The invention relates to new anthracycline derivatives having cytostatic activity and the general formula I, which are optionally in the form of a salt of an inorganic or organic acid, ##STR1## in which the substituents have the following meaning: R.sup.1 is hydrogen or a hydroxyl group,

Growing community of inventors

Marburg, Germany

Manfred Gerken